UBS analyst Ashwani Verma reiterated a Neutral rating and $119.00 price target on Biogen (NASDAQ: BIIB).The analyst commented, "After hitting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE